Continuing Education Courses
STP will offer one continuing education course in-person at the 2027 Annual Symposium and three courses virtually at other times. More information about the virtual courses is below.
Sunday, June 27
CE1 1:30 PM–5:00 PM
- Digital Pathology in Toxicologic Pathology: From First Whole Slide Images through Validation to Advanced AI
Co-Chairs: Aleks Zuraw, DVM, PhD, DACVP, Charles River Laboratories, Digital Pathology Place; Danielle Brown, DVM, MS, MBA, DACVP, DABT, FIATP, Charles River Laboratories; Famke Aeffner, DVM, PhD, DACVP, DABT, FIATP, Amgen
Digital pathology is advancing rapidly within toxicologic pathology and offers practical opportunities to streamline workflows, support multi-site collaboration, and enable new analytical approaches. This course will provide a structured overview of key components of a digital pathology ecosystem, designed to support participants across a broad range of prior experience.
Topics will include whole slide imaging fundamentals, platform and infrastructure considerations, workflow integration, and principles for validating digital pathology in both single site and multi-site settings. The course will address logistical aspects relevant to diverse organizations, including data handling, interoperability, and considerations for institutional deployment of digital pathology.
Practical elements of implementing digital pathology will include factors that influence image usability and downstream analysis, as well as the role of consistent processes and automations in enabling efficient digital review.
Building on these foundations, the course will discuss the role of automated tissue image analysis for scientific insights, efficiency gains and workflow optimization, along with approaches for leveraging digital slides as study data suitable for multimodal computational pipelines.
Virtual Continuing Education Courses
Friday, February 19, 2027, 12:00 Noon–3:45 PM EDT
- Drug Class Effects and Potential Pitfalls in Preclinical Clinical Pathology Testing – Part I
Co-Chairs: Cory Sims, DVM, DACVP, Roche Diagnostics; Valerie Wong, DVM, PhD, DACVP, DABT, Novartis Institutes for BioMedical Research; Liza Bau-Gaudreault, DVM, MSc, DES, DACVP, Charles River Laboratories
As we gain more experience with novel drug modalities, unique platform-related effects on clinical pathology parameters are becoming increasingly apparent. Recognizing these expected effects—and distinguishing them from novel or unanticipated findings—is critical for accurate interpretation of preclinical data, particularly as next-generation therapeutics enter development. At the same time, decisions regarding when and how to incorporate non standard clinical pathology endpoints to better characterize the onset, progression, and relevance of class effects are playing an increasingly important role in study design and regulatory success. This course is designed to help scientists working in the preclinical environment place clinical pathology findings into appropriate biological and programmatic context. Through modality-focused discussions, participants will learn to anticipate class-related effects, recognize potential pitfalls in data interpretation, and make informed decisions about test selection, assay methodology, and study design to optimize study outcomes and support compound advancement.
Following a brief introductory presentation, the course will consist of five 50-minute sessions (40 minutes of lecture and 10 minutes for Q&A). Each session will review known and emerging effects on clinical pathology parameters associated with a specific class of test articles, including antisense oligonucleotides and GalNAc conjugates, siRNA therapeutics, antibody-drug conjugates, lipid nanoparticles, and gene therapies. Speakers will also address key considerations and challenges related to assay selection and analytical methodology in the preclinical setting. A 25-minute open question-and-answer session will conclude the course.
Friday, February 26, 2027, 12:00 Noon–3:45 PM EDT
- Drug Class Effects and Pitfalls in Preclinical Clinical Pathology - PART II
Co-Chairs: Cory Sims, DVM, DACVP, Roche Diagnostics; Valerie Wong, DVM, PhD, DACVP, DABT, Novartis Institutes for BioMedical Research; Liza Bau-Gaudreault, DVM, MSc, DES, DACVP, Charles River Laboratories
As we gain more experience with novel drug modalities, unique platform-related effects on clinical pathology parameters are becoming increasingly apparent. Recognizing these expected effects—and distinguishing them from novel or unanticipated findings—is critical for accurate interpretation of preclinical data, particularly as next-generation therapeutics enter development. At the same time, decisions regarding when and how to incorporate non standard clinical pathology endpoints to better characterize the onset, progression, and relevance of class effects are playing an increasingly important role in study design and regulatory success. This course is designed to help scientists working in the preclinical environment place clinical pathology findings into appropriate biological and programmatic context. Through modality-focused discussions, participants will learn to anticipate class-related effects, recognize potential pitfalls in data interpretation, and make informed decisions about test selection, assay methodology, and study design to optimize study outcomes and support compound advancement.
Following a brief introductory presentation, the course will consist of five 50-minute sessions (40 minutes of lecture and 10 minutes for Q&A). Each session will review known and emerging effects on clinical pathology parameters associated with a specific class of test articles, including antisense oligonucleotides and GalNAc conjugates, siRNA therapeutics, antibody-drug conjugates, lipid nanoparticles, and gene therapies. Speakers will also address key considerations and challenges related to assay selection and analytical methodology in the preclinical setting. A 25-minute open question-and-answer session will conclude the course.
Friday, August 27, 2027, 12:00 Noon–3:45 PM EDT
- Preclinical Medical Device Pathology: Navigating the Wild West
Co-Chairs: Maria Bates, DVM, DACVP, Inotiv; Kate Watson, DVM, PhD, DACVP, Inotiv; Cat Cowan, DVM, DACVP, Inotiv; Molly Friedemann DVM, DACP, Inotiv
Preclinical evaluation of medical devices is an expanding and evolving area of preclinical research, and the framework for evaluating device safety and tissue compatibility differs substantially from traditional pharmaceutical toxicology. Unlike small molecules and biologics, medical devices interact with tissues through mechanical forces, biomaterials, and surgical implantation, often requiring distinct approaches to study design, regulatory interpretations, and histopathologic methods that are unfamiliar to both recent graduates as well as many experienced toxicologic pathologists.
This continuing education course will provide a practical overview of medical device pathology with emphasis on study design, regulatory expectations, surgical models, and interpretation of tissue responses across device types and species. Key regulatory frameworks including ISO 10993 biocompatibility standards (Parts 1, 6, and 11), FDA guidance, and selected ASTM standards will be discussed in the context of real-world study design decisions. Participants will also learn how device-specific factors – including implantation techniques, device materials, histologic processing methods (paraffin versus plastic), and species selection – influence the interpretation of histopathologic findings. Through case-based examples spanning cardiovascular, neurologic, and ablative device technologies, this course will highlight common pitfalls, sources of misinterpretation, and strategies for generating interpretable pathology data. By the end of the course, participants will have a practical framework for approaching medical device studies and understanding how device pathology differs from traditional toxicologic pathology.
Friday, September 17, 2027, 12:00 Noon–3:45 PM EDT
- That Causes Cancer in Rats! Mechanisms of Non-Genotoxic Cancer in Rodents
Co-Chairs: Rani Seller, DVM, PhD, DACVP, University of North Carolina
The rodent bioassay remains a central tool in evaluating the carcinogenic potential of environmental, industrial, and pharmaceutical chemicals. The carcinogenicity bioassay is a standardized, long-term in vivo study designed to assess the potential of non-genotoxic chemicals to induce neoplastic lesions following chronic exposure. Typically conducted in rats and mice over most of their lifespan (approximately 18–24 months) or in alternative mouse models over a 6 month period, the bioassay involves administration of the test substance at multiple dose levels via relevant exposure routes, followed by comprehensive gross and histopathological evaluation of all major tissues. The primary objective of the assay is hazard identification—specifically, to determine whether sustained exposure increases the incidence, latency, or spectrum of benign or malignant tumors in comparison with untreated controls. Data generated from rodent carcinogenicity bioassays form a foundational component of the regulatory risk assessment, particularly in the absence of adequate human epidemiological evidence. Several species-specific mechanisms of non-genotoxic carcinogenicity have been identified in rodents. Familiarity with these rodent-specific mechanisms is essential for appropriate cancer risk assessment packages. This session will review current approaches to assessing chemical cancer potential as well as several well-defined non-genotoxic mechanisms of carcinogenicity and their relevance to humans.
Continuing Education Courses
Continuing Education Chair: Saravanan Kaliyaperumal, BVSc & AH, MPH, PhD, DACVP, DABT, Johnson & Johnson
Continuing Education Co-Chair: Karyn Enos, DVM, MS, DACVP, Novartis
A separate registration fee is charged to attend the Sunday Continuing Education Course. View CE courses for details.
If you have previously registered for the meeting and would like to add a CE course, please contact STP Headquarters for processing. You may also mail or fax a Registration Form and indicate that you are adding a CE course.